Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Farydak (panobinostat), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), melflufen, MOR202, oprozomib, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Jul 30, 2015 11:54 pm | No Comment ]
The Myeloma Quiz – July 2015

The American Society of Clinical Oncology (ASCO) meeting in any given year is hit-or-miss as far as breaking research for multiple myeloma goes.

However, at ASCO 2015, there were no two views among myeloma experts. It was probably one of the most significant ASCO meetings as far as pre­senta­tions of abstracts that have the potential to alter the land­scape of myeloma treat­ment in the near future.

There is no way to do justice to all the presentations at ASCO this year. However, I have tried to prepare a quiz …

Read the full story »
[ by | Jul 30, 2015 3:26 pm | 4 Comments ]
Elotuzumab – A Closer Look At The ELOQUENT-2 Clinical Trial Results

Earlier this week, Bristol-Myers Squibb announced that it had filed an appli­ca­tion to have elotuzumab approved in Europe as a new treat­ment for multiple mye­lo­ma patients who have received one or more prior ther­a­pies (see related Bristol-Myers press release).

An important part of elotuzumab’s European approval appli­ca­tion will be efficacy and safety data from a Phase 3 clinical trial known as ELOQUENT-2. These re­sults drew significant attention when they were presented at this summer’s Amer­i­can Society of Clinical Oncology (ASCO) and Euro­pean …

Read the full story »
[ by | Jul 7, 2015 2:16 pm | 7 Comments ]
Daratumumab Expanded Access Program Initiated

A new program has been started that will make it easier for re­lapsed mul­ti­ple myeloma patients in the United States to be treated with the in­ves­ti­ga­tion­al drug daratumumab.

Johnson & Johnson (NYSE:JNJ), which is developing dara­tu­mu­mab in col­lab­o­ra­tion with the Danish biotechnology company Genmab, has ini­ti­at­ed an “ex­panded access program” – a special kind of clinical trial – to broaden op­por­tu­ni­ties for qualify­ing U.S. myeloma patients to be treated with the drug.

The program is expected to remain in place until a decision is made by the U.S. …

Read the full story »
[ by | Jun 26, 2015 3:03 pm | One Comment ]
Farydak Gets Positive Opinion From European Advisory Committee; Approval Expected Within Three Months

An advisory committee of the European Medicines Agency has issued a positive opinion regarding European approval of Farydak (panobinostat) for the treat­ment of cer­tain patients with multiple myeloma.

Specifically, the Committee for Medicinal Products for Human Use (CHMP) rec­om­mended that Farydak be approved for use in com­bi­na­tion with Velcade (bor­tez­omib) and dexa­meth­a­sone (Decadron) for the treatment of re­lapsed and/​or refractory multiple myeloma patients who have received at least two prior treatment regimens.

The two prior regimens must include Velcade and at least one treatment from the immunomodulatory class …

Read the full story »
[ by | Jun 25, 2015 3:02 pm | 5 Comments ]
Multiple Myeloma Highlights From The 2015 ASCO, EHA, And IMWG Annual Summit Meetings

The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral presentations, posters, and e-abstracts summarizing the results of new oncology- and hematology-related research.

Included in the research presented at the two meetings were more than 200 studies discussing new multiple myeloma-related findings.

In addition to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Working …

Read the full story »
[ by | Jun 7, 2015 1:15 pm | No Comment ]
ASCO 2015 Multiple Myeloma Update – Poster Presentations: Potential New Myeloma Therapies

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a number of poster presentations related to multiple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, research results are made available for review by meeting attendees in the form of posters, each of which summarizes the results of a single study. Each poster is typically about two feet high by three or four feet in length, and all posters during a ses­sion are displayed throughout a large conference hall.

Most of …

Read the full story »